Nomura Holdings
ACAD icon

Nomura Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Nomura Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$668K Buy
30,000
+11,900
+66% +$284K ﹤0.01% 1275
2025
Q4 		$483K Buy
+18,100
New +$433K ﹤0.01% 1535
2025
Q3 		– Sell
-24,100
Closed -$520K – 1840
2025
Q2 		$520K Buy
+24,100
New +$448K ﹤0.01% 1129

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nomura Holdings's ACAD Position: Q4 2025 in Review

Nomura Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 101,950 shares — an estimated $2.44M sold.

Nomura Holdings first reported a position in ACAD in Q3 2013 and held it in 7 quarters. The position peaked at $14.8M in Q4 2022. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Nomura Holdings reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Nomura Holdings sold 101,950 Acadia Pharmaceuticals shares in Q4 2025, an estimated $2.44M.
  • Nomura Holdings first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Nomura Holdings's Acadia Pharmaceuticals position peaked at $14.8M in Q4 2022.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.